1.	Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC6125, EudraCT : 2005-005026-31, AVE0005A /3001, NCT00327444
2.	Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC6546, EUDRACT : 2006-004756-20, NCT00519285
3.	A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC10261, EudraCT 2007-000819-29, NCT00532155
4.	Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC10262, EudraCT 2007-000820-42, NCT00561470
5.	VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MDA-2006-0329, P50CA083639, P30CA016672, CDR0000530016, 7757, NCT00436501
6.	A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
7.	Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARD6123, AVE0005B/2001, NCT00284141
8.	Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARD6122, AVE0005, NCT00327171
9.	Phase II Study of VEGF Trap in Patients With Previously Treated Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0537, N0537, NCT00369655
10.	VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: NABTC-0601 CDR0000495275, U01CA062399, ABTC-0601, NABTC-0601, NCT00369590
11.	VEGF Trap in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000508798, PMH-PHL-051, NCI-7502, 7502, NCT00390234
12.	VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000518293, PMH-PHL-050, NCI-7498, 7498, NCT00407654
13.	VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000518346, P30CA033572, CCC-PHII-76, 7533, NCT00407485
14.	AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARD6772, EUDRACT: 2006-000604-16, NCT00396591
15.	VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000535719, P30CA033572, CCC-PHII-77, 7522, NCT00450255
16.	VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00597, U10CA027469, CDR0000540237, GOG-0229F, NCT00462826
17.	Aflibercept in Treating Patients With Myelodysplastic Syndromes Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000558101, P30CA033572, CCC-PHII-73, 7518, PHII-73, NCT00509249
18.	Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00178, CDR0000608163, 08-066, N01CM62206, MSKCC-08066, 7508, NCT00729157
19.	Phase II Randomized Study of Topotecan Hydrochloride With Versus Without Aflibercept in Patients With Extensive Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0802, S0802, NCT00828139
20.	Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC10668, EudraCT 2008-004178-41, NCT00851084
21.	Phase I Study of VEGF Trap in Patients With Incurable Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 25 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-01131, REGENERON-VGFT-ST-0103, NCI-G02-2065, NCT00036946
22.	Phase I Extension Study of VEGF Trap in Patients With Incurable Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 25 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-02020, REGENERON-VGF-ST-0105, NCI-G-02-2101, NCT00045266
23.	Phase I Study of Intravenous VEGF Trap in Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-03138, REGENERON-VGFT-ST-0304, NCT00082823
24.	Phase I Study of Intravenous VEGF Trap in Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-03137, REGENERON-VGFT-ST-0202, NCT00083213
25.	A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients Phase: Phase I Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TED10089, NCT00479076